Skeletal muscle atrophy affects over 60 million people in the US alone but lacks a pharmacologic therapy. To help address this issue, Emmyon is discovering and developing novel pharmaceuticals for skeletal muscle atrophy. By increasing skeletal muscle, these novel compounds also reduce body fat and demonstrate pre-clinical efficacy against obesity and type 2 diabetes.
To discuss licensing or partnership opportunities in pharmaceuticals, please email emmyon@emmyon.com or contact us via LinkedIn.